Envestnet Asset Management Inc. Boosts Holdings in AbbVie Inc. $ABBV

23 Sep 2026, 19:43 by Scott Moore · The Cerbat Gem

Envestnet Asset Management Inc. boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 0.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 4,886,670 shares of the company’s stock after buying an additional 33,103 shares during the quarter. Envestnet Asset Management Inc.’s holdings in AbbVie were worth $1,229,679,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its position in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares during the period. Premier Financial Group bought a new stake in shares of AbbVie during the 2nd quarter valued at $250,000. Security National Bank of Sioux City Iowa IA grew its position in shares of AbbVie by 13.3% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 16,964 shares of the company’s stock valued at $4,269,000 after acquiring an additional 1,995 shares during the period. Reynders McVeigh Capital Management LLC increased its stake in shares of AbbVie by 0.4% in the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 29,167 shares of the company’s stock worth $7,340,000 after purchasing an additional 115 shares in the last quarter. Finally, Bullseye Investment Management LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth $170,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Rinvoq wins EU approval for pediatric arthritis: The European Commission approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, at least one DMARD. The approval adds a new pediatric use, includes an oral solution, and brings Rinvoq to 11 approved indications in Europe. The commercial impact is likely modest initially, but the decision expands the drug’s addressable population and reinforces its growth potential. AbbVie Announces European Commission Approval of Rinvoq
Positive Sentiment: Potential pipeline collaboration: Iambic reportedly filed for an IPO after signing AbbVie as a partner. Although financial terms and the specific assets involved were not provided, the arrangement could give AbbVie access to additional computational drug-discovery capabilities and future pipeline opportunities. Iambic files IPO after signing AbbVie as new partner
Neutral Sentiment: Aesthetic business initiatives: Allergan Aesthetics launched AA Signature with SKIN360 in the United States, a multimodal consultation and provider-education program. The initiative may support customer engagement and procedure demand, but no immediate revenue impact was disclosed. Allergan Aesthetics Debuts AA Signature
Negative Sentiment: Bearish analyst commentary: A Seeking Alpha analysis argues that revenue pressure and weakening earnings support a “sell” view. This contrasts with AbbVie’s latest reported quarterly revenue growth and earnings beat, but highlights investor concerns over the sustainability of growth and the stock’s elevated valuation. AbbVie: Revenue Pressure And Weakening Earnings Support a Sell

AbbVie Trading Up 0.1%

Shares of ABBV traded up $0.22 during trading hours on Wednesday, reaching $265.43. 3,445,647 shares of the stock traded hands, compared to its average volume of 6,531,572. The company has a market cap of $468.96 billion, a P/E ratio of 74.98, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29. The company’s 50-day moving average price is $256.31 and its two-hundred day moving average price is $232.58. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $269.39.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Analyst Ratings Changes

Several research firms recently weighed in on ABBV. HSBC lifted their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. raised their price objective on AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AbbVie in a research report on Wednesday, September 16th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective for the company in a research note on Thursday, August 13th. Finally, BMO Capital Markets increased their target price on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $276.64.

Get Our Latest Analysis on ABBV

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.